Comparison of recombinant granulocyte colony-stimulating factor, recombinant human granulocyte-macrophage colony-stimulating factor and placebo for treatment of septic preterm infants

Abstract

The neutrophil count in the rG-CSF-treated group increased significantly faster than that in the placebo or rhuGM-CSF group.

Haematological abnormalities in neonatal necrotizing enterocolitis

“…Overall, rG-CSF may be more efficacious in raising neutrophil counts than GM-CSF (23). The use of these myelopoietic growth factors in NEC is extrapolated from studies on neonatal sepsis and neutropenia.…”

Neonatal transfusion practice

“…[71][72][73][74][75] However, the available evidence suggests that neither agent given as prophylaxis, or as adjuvant therapy during neonatal sepsis, significantly improves outcome. [71][72][73][74][75][76][77][78][79][80] Further trials are in progress, but again these agents cannot, as yet, be recommended in the treatment of sepsis in standard neonatal practice. [76][77][78][79][80] THROMBOPOIETIN AND INTERLEUKIN 11 Both these agents are currently being evaluated in adults and children for their ability to stimulate platelet production and ameliorate thrombocytopenia.…”

Sepsis associated with immunosuppressive medications: An evidence-based review

“…G-CSF and GM-CSF have also been used successfully in neonatal sepsis, in the presence or absence of neutropenia (104,105). There is some evidence that GM-CSF may improve survival in neonates with sepsis and neutropenia (106).…”